Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden

@article{Ericsson2013EvaluationOT,
  title={Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden},
  author={{\AA}sa Ericsson and R. F. Pollock and Barnaby Hunt and William J. Valentine},
  journal={Journal of Medical Economics},
  year={2013},
  volume={16},
  pages={1442 - 1452}
}
Abstract Objective: To evaluate the annual cost-utility of insulin degludec compared with glargine in patients with: type 1 diabetes (T1D), type 2 diabetes receiving basal-only therapy (T2D-BOT), and type 2 diabetes receiving basal-bolus therapy (T2B-BB) in Sweden. Methods: A cost-utility model was programmed in Microsoft Excel to evaluate clinical and economic outcomes. The clinical trials were designed as treat-to-target, with insulin doses adjusted in order to achieve similar glycemic… 

Cost-effectiveness of switching to insulin degludec from other basal insulins in real-world clinical practice in Italy

Under routine care, switching to degludec is dominant, compared with continuing previous basal insulin, in Italian patients with T1D or T2D, meaning that patient health was improved in terms of QALYs with lower healthcare costs.

Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Adults with Type 1 and Type 2 Diabetes Mellitus

IDeg is a cost-effective alternative to IGlar U100 for patients with diabetes in the UK, and it is likely to be cost- effective versus two new-to-market basal insulin analogues, with incremental cost-effectiveness ratios below the accepted threshold.

A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark

Over a 1-year time horizon, insulin degludec resulted in cost savings relative to insulin glargine in T1D and T2DBOT cohorts, while being cost-effective in T2 DBB.

Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16)

The authors' long-term modeling analysis suggested that degludec was cost effective (from the perspective of NHS England) versus glargine U100 in basal–bolus regimens for patients with T2D at high CV risk.

Cost-effectiveness of switching to insulin degludec from other basal insulins: evidence from Swedish real-world data

It was estimated that switching to IDeg from other basal insulins translated into QALY gains including improved life expectancy and health-related quality of life, as well as dominant ICER, meaning cost-savings for the healthcare system.

Insulin degludec versus insulin glargine U100 for patients with type 1 or type 2 diabetes in the US: a budget impact analysis with rebate tables

Using IDeg instead of IGlar at list price could result in a modest increase in costs when considering insulin and hypoglycemia costs alone, but modest incremental rebates with IDeg would result in cost neutrality relative to I Glar.

Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria

Degludec is a cost-effective alternative to biosimilar glargine U100 for patients with T1DM and T2DM in Bulgaria and could be of particular benefit to those patients suffering recurrent hypoglycaemia and those who require additional flexibility in the dosing of insulin.

Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspective

Insulin degludec was projected to be cost-effective or dominant versus other basal insulins for the treatment of T1D and T2D in Sweden and was associated with improved quality-adjusted life expectancy and lower incidences of diabetes-related complications.

Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U100 in Patients with Type 1 and Type 2 Diabetes Mellitus in Serbia

Degludec is a cost-effective alternative to glargine U100 for patients with T1DM and T2DM in Serbia and may particularly benefit those suffering from hypoglycaemia or where the patient would benefit from the option of flexible dosing.

References

SHOWING 1-10 OF 37 REFERENCES

Health economic evaluation of insulin glargine vs NPH insulin in intensified conventional therapy for type 1 diabetes in Germany

GLA appears to be cost effective or even cost saving among type 1 diabetics with basal bolus therapy from the perspective of SHI compared to NPH depending on the scenario chosen.

Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes.

The addition of biphasic or prandial insulin aspart reduced levels more than the addition of basal insulin detemir but was associated with greater risks of hypoglycemia and weight gain.

Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review

There appear to be no reported differences between IDeg and IGlar, detemir, or BIAsp 30 in the reduction of the primary efficacy end-points of HbA1c and mean fasting plasma glucose (FPG) concentrations.

Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus.

The analysis suggests, if at all only a minor clinical benefit of treatment with long-acting insulin analogues for patients with diabetes mellitus type 2 treated with "basal" insulin regarding symptomatic nocturnal hypoglycaemia was statistically significantly lower in patients treated with either insulin glargine or detemir.

Cost-effectiveness of sensor-augmented pump therapy in adults with type 1 diabetes in the United States.

  • S. KambleK. SchulmanS. Reed
  • Medicine, Political Science
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
  • 2012

Insulin Degludec Once-Daily in Type 2 Diabetes: Simple or Step-Wise Titration (BEGIN: Once Simple Use)

Insulin degludec was effective and well tolerated using either the Simple or Step-wise titration algorithm, and may enable patient empowerment through self-titration, improved convenience, and reduced costs.

Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials

This pre‐planned meta‐analysis aimed to demonstrate the superiority of IDeg over insulin glargine (IGlar) in terms of fewer hypoglycaemic episodes at equivalent HbA1c in type 2 and type 1 diabetes mellitus (T2DM/T1DM).

Cost of hypoglycemia in patients with Type 2 diabetes in Sweden.

The results indicate that hypoglycemic events lead to substantial costs, but data are scarce and more studies are needed to better understand the cost and consequences of hypoglycemia.

Cost effectiveness of self monitoring of blood glucose in patients with non-insulin treated type 2 diabetes: economic evaluation of data from the DiGEM trial

Self monitoring of blood glucose with or without additional training in incorporating the results into self care was associated with higher costs and lower quality of life in patients with non-insulin treated type 2 diabetes.